Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Truist Securities Maintains Hold on Quest Diagnostics, Lowers Price Target to $145-Report Released on 1 February 2024

Author: Benzinga Newsdesk | February 02, 2024 04:05pm

Truist Securities analyst David Macdonald maintains Quest Diagnostics (NYSE:DGX) with a Hold and lowers the price target from $150 to $145.

Posted In: DGX